Anticoagulation for cancer-associated venous thromboembolism (VTE) can be challenging
due to complications—including bleeding and potential drug–drug interactions with …

Clinicians have been more and more often encountering patients with venous
thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis, leading …

Background Pulmonary endarterectomy (PEA), pulmonary arterial hypertension (PAH)
therapy and balloon pulmonary angioplasty (BPA) are currently accepted therapies for …

Background There has been limited data on anticoagulation strategies and long-term
recurrence in patients with venous thromboembolism (VTE) in the era of direct oral …

Background: There is a paucity of data on the management and prognosis of cancer-
associated venous thromboembolism (VTE), leading to uncertainty about optimal …

Background Recently, direct oral anticoagulants have been introduced for venous
thromboembolism (VTE), which might change the management strategies of VTE. However …

Background: The simplified pulmonary embolism severity index (sPESI) score has been
reported to be useful in predicting 30-day mortality for patients with pulmonary embolism …

Background There is a paucity of data on real-world management strategies and clinical
outcomes of cancer-associated venous thromboembolism (VTE) in the direct oral …

Background: Coronavirus disease 2019 (COVID-19) reportedly causes venous
thromboembolism (VTE), but the status of this complication in Japan was unclear. Methods …

Anticoagulation therapy is the first line and drug of choice for both the treatment and
prophylaxis of venous thromboembolism (deep vein thrombosis and/or pulmonary …